STOK Stoke Therapeutics Inc

Price (delayed)

$30.22

Market cap

$1.88B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.84

Enterprise value

$1.73B

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 81
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 22

Stoke Therapeutics, is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company's proprietary TANGO (Targeted Augmentation of ...

Highlights
Stoke Therapeutics's quick ratio has soared by 70% from the previous quarter and by 7% YoY
Stoke Therapeutics's equity has increased by 13% YoY and by 12% from the previous quarter
The company's gross profit has shrunk by 83% YoY and by 83% QoQ
The revenue has plunged by 83% YoY and by 83% from the previous quarter

Key stats

What are the main financial stats of STOK

STOK stock price

How has the Stoke Therapeutics stock price performed over time
Intraday
2.58%
1 week
-4.4%
1 month
-11.59%
1 year
176.23%
YTD
-4.79%
QTD
-7.19%

Financial performance

How have Stoke Therapeutics's revenue and profit performed over time
Revenue
$32.08M
Gross profit
$32.08M
Operating income
-$185.25M
Net income
-$169.77M
Gross margin
100%
Net margin
-529.2%
The company's gross profit has shrunk by 83% YoY and by 83% QoQ
The revenue has plunged by 83% YoY and by 83% from the previous quarter

Price vs fundamentals

How does STOK's price correlate with its fundamentals

Growth

What is Stoke Therapeutics's growth rate over time

Valuation

What is Stoke Therapeutics stock price valuation
P/E
N/A
P/B
4.53
P/S
59.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
53.82
The P/B is 47% above the 5-year quarterly average of 3.0 and 10% above the last 4 quarters average of 4.0
Stoke Therapeutics's equity has increased by 13% YoY and by 12% from the previous quarter
The price to sales (P/S) is 174% higher than the last 4 quarters average of 21.1 and 19% higher than the 5-year quarterly average of 48.6
The revenue has plunged by 83% YoY and by 83% from the previous quarter

Efficiency

How efficient is Stoke Therapeutics business performance

Dividends

What is STOK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for STOK.

Financial health

How did Stoke Therapeutics financials performed over time
STOK's current ratio has surged by 70% since the previous quarter and by 7% year-on-year
Stoke Therapeutics's quick ratio has soared by 70% from the previous quarter and by 7% YoY
STOK's debt is 100% smaller than its equity
Stoke Therapeutics's equity has increased by 13% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.